The severity of β-thalassemia syndrome is associated with precipitation of the cytotoxic excessive free α-hemoglobin. We have established a therapy strategy aiming at stabilizing excessive free α-hemoglobin by decreasing its precipitation using erythroid differentiation-related factor (EDRF). To identify the functional EDRF promoter, different length of human EDRF promoter sequence was cloned upstream of green fluorescence protein (GFP) to drive GFP expression. After transfection, the intensity of GFP expression was monitored by microscopy and fluorescence activated cell sorter analysis. The 372 base pair sequence (−116∼+256 bp) was found to be most effective to induce the GFP expression and thereby cloned into pcDNA-EDRF vector to drive EDRF expression. After introducing pcDNA-EDRF vector into MEL cells and healthy mice, we confirmed high EDRF expression at both mRNA and protein levels using reverse transcription polymerase chain reacion and enzyme-linked immunosorbent assay. We further tested the function of EDRF overexpression in β-thalassemia mice by pcDNA-EDRF injection. One week later after treatment, the hemoglobin value, poikilocytosis and target cells of β-thalassemia mice were found to be ameliorated obviously. These results indicated that EDRF is a potential therapeutic target by improving hematological parameters of β-thalassemia.
Introduction
Erythroid differentiation-related factor (EDRF) was originally identified as a protein that showed a decrease in expression in the hematopoietic tissues of rodents and cattle infected with transmissible spongiform encephalopathies (Miele et al. 2001) . EDRF was renamed as α-hemoglobin stabilizing protein (AHSP) after it was found that it binds specifically to α-hemoglobin in vitro (Gell et al. 2002; Kihm et al. 2002; Santiveri et al. 2004) . EDRF specifically binds to the α-chains of hemoglobin but not to the β-chains or to tetrameric hemoglobin.
EDRF may be a modifier gene to stabilize α-globin in the β-thalassemia syndrome (Luzzatto et al. 2002; dos Santos et al. 2004 dos Santos et al. , 2008 , which is caused by β-globin gene abnormality. β-Thalassemia is one of the most common genetic diseases, especially in the Mediterranean region, the Middle East and South East Asia. Decreased or defective EDRF would be expected to worsen the phenotype of β-thalassemia because of the cytotoxic effects of excessive free α-hemoglobin. In a mouse model, EDRF deficiency leads to wellcompensated hemolysis with Heinz body formation, reticulocytosis, and increased apoptosis of erythroid precursors (Kong et al. 2004) . When EDRF-deficient mice were bred to β-thalassemia mice, loss of EDRF increased the severity of the thalassemia (Kong et al. 2004) . These studies also suggested that EDRF might play a role in unexplained Heinz body hemolytic anemia in humans.
In this article, a new approach by using EDRF to stabilize the excess α-globin was explored to β-thalassemia therapy. Several green fluorescence protein (GFP) vectors driven by different length EDRF promoters were constructed to investigate the gene regulation sequence of EDRF. The most effective promoter was chosen to drive EDRF expression effectively in vivo to investigate the therapy action of EDRF to ameliorate the anemia syndrome.
Material and methods

EDRF gene promoters amplified by PCR
Human EDRF gene sequence was analyzed on the NCBI web (http://www.ncbi.nlm.nih.gov/); the PCR primers (Table 1) were designed as follows to clone the different kinds of EDRF gene promoter. The sites of the primers are described in Figure 1 . The promoters were PCR amplified for 32 cycles in a PCR machine (Eppendorf): the program consisted of denaturing at 94
• C for 45 s, annealing for 45 s (for Tm value, see Table 1) , and synthesizing at 72
• C for 60 s. The PCR products were then run on 2% agarose electrophoretic gel.
GFP vectors constructed to study the effect of promoters The GFP vectors were constructed driven by different length of promoters. At first, the GFP gene was cut from pGEP-N1 and cloned into pcDNA(3.1+)/ZEO vector to form pcDNA-GFP vector using restriction endonulease (EcoRI and NotI). Then the promoters were amplified by PCR from human genome DNA and cloned into pUCm-T vector to construct pUCm-promoter vector. The promoters were cut from pUCm-promoter by EcoRV and Hind III, which were cloned into pcDNA-GFP vector to construct pcDNA-Pro-GFP vector through NruI and Hind III.
Cell culture and transfection
Mouse embryonic fibroblast cells (NIH3T3) were cultivated in Dulbecco's modified eagle's medium (DMEM, Gibco) supplemented with 10% fetal calf serum. Mouse erythroleukemia (MEL) cells were cultivated in DMEM with 15% fetal calf serum and 1.5% dimethylsulfoxide (DMSO, Sigma) for the induction of maturation. All cells were grown at 37
• C with 5% CO2. 5×10
5 cells were transfected with 1 µg of plasmid and 2.5 µL of lipofectamine (Invitrogen) according to the manufacturer's instructions.
GFP detection and analysis Fluorescence detection. Following 72 hours incubation after the transfection, each group of cells was observed under the fluorescence microscope (Leica, DMRXA2). For the NIH3T3 cells, trypsinization was needed.
Fluorescence activated cell sorter (FACS) analysis. The cells were also collected and washed with phosphate buffered saline. The GFP expression was then analyzed by a FACS (Becton Dichinson FACS caliber) to reflect the activation of different length of EDRF promoter.
The constructed human EDRF vector driven by the effective promoter After GFP expression was detected, the most effective promoter was determined according to the highest expression of GFP. Then the effective promoter was designed to drive the EDRF expression. The EDRF gene and its promoter were cloned by primers. F4: 5'-GGCCTTGTTATCTTTCTA CCT-3' (around F3 primer, −112 bp); R3:5'-TTCTTGTTT CTGCCACCC-3' (+1168 bp). Sequences were PCR amplified for 30 cycles in a PCR machine (Eppendorf). The program was denaturing at 94
• C for 60 s, annealing at 54
• C for 60 s, and synthesizing at 72
• C for 90 s. The PCR products were then run on 1.5% agarose electrophoretic gel. The EDRF and its promoter were inserted to pUCm-T vector as pUCm-EDRF vector. Then, the EDRF gene and its promoter were cut by EcoRV and BamHI and cloned into pcDNA(3.1+)/ZEO vector to form pcDNA-EDRF vector through NruI and BamHI.
Detection of human EDRF vector expression RT-PCR. Total RNA was isolated according to the manufacturer's instructions (Gentra, Total RNA and isolation KIT), 1.5 µg of total RNA from the cells was mixed with 2 µL of reverse transcriptase buffer, 4 µL of dNTP (10 mM), 0.5 µL of oligo-dT (0.5 mg/mL) and 1 µL of reverse transcriptase (New England). Diethyl pyrocarbonatetreated water was used to make a total volume of 20 µL. Complementary DNA (cDNA) was then synthesized at 37
• C for 1 h followed with heated at 70
• C for 10 min, and left on ice for at least 2 min. EDRF cDNAs were then PCR amplified for 28 cycles in a PCR machine (Eppendorf). The program was denaturing at 94
• C for 45 s, annealing at 57
• C for 45 s, and synthesizing at 72
• C for 45 s. Forward: 5'-CGCAGGATTGAAGGAGTTC-3'; reverse: 5'-GTGTCAGGGTAGAGTGGC-3'. β-Actin cDNA was used as a reference; forward: 5'-CTACAATGAGCTGCGTGTG GC-3'; reverse: 5'-CAGGTCCAGACGCAGGATGGC-3'. The PCR products were then run on 1.5% agarose electrophoretic gel.
ELISA. The measurement procedure is briefly described as follows: the MEL cells or mouse blood cells were lysed and then incubated into each plate well, followed by adding goat anti-human EDRF monoclonal antibodies (Santa Cruz Biotechnology), secondary antibodies (rabbit anti-goat IgG, Abcam) and their substrate in turn. The optical density of the reaction was determined spectrophotometrically at 450 nm (OD450nm) by an ELISA reader (ELX800).
Human EDRF expression in mice
In order to evaluate the expression of human EDRF gene in mice, pcDNA-EDRF plasmid was isolated according to the manufacturer's instructions (Promega). Then 5 healthy mice were chosen for experiment. 30-35 µg of pcDNA-EDRF plasmid in 800 µL saline was injected into the tail veins of the healthy experiment mice. Seven days after the treatment, the peripheral blood cells of the mice were analyzed to test human EDRF expression.
To investigate whether the β-thalassemia anemia syndromes could be ameliorated by EDRF, 5 β-thalassemia mice were injected with 30-35 µg of pcDNA-EDRF plasmids in 800 µL saline by tail vein. The β-thalassemia mice (B6; 129P2-Hbb tm2Unc ) were obtained from the Jackson Laboratory (JAX). These mice are heterozygotes (Hbb th−4 /Hbb + ) carrying a human gene with β IV S−2−654 C→T splicing mutation, manifesting a typical signs of a moderate form of β-thalassemia (Lewis et al. 1998) . One week after treatment, hematologic studies were analyzed.
Hematologic studies
Mouse peripheral blood smears were made from 1 to 2 µL of blood collected in heparinized microhematocrit tubes, air dried and stained with Wright staining. Whole blood samples of mice at least 6 weeks old were collected in 40 µL microhematocrit tubes containing 2 µL of 0.5 M EDTA (pH 8). The red blood cells count, hemoglobin and reticulocyte counts for each sample were determined using a Hematology Analyzer (KX-21, Sysmex) equipped with software to analyze murine cells.
Results
pcDNA-GFP vectors driven by different length promoters
To investigate the effective length of EDRF promoter, five kinds of different-length promoters (697 bp, 496 bp, 484 bp, 372 bp, 283 bp) were amplified by PCR (Fig. 2a) and cloned into pUCm-T vector. Then, the promoters were cloned into pcDNA-GFP vector to construct pcDNA-Pro-GFP vector, which was confirmed by two groups of restriction endonucleases: Not I, Not I+Hind III (Fig. 2b) .
Expression of GFP
After the above vectors were constructed and transfected to NIH3T3 cells and MEL cells, the GFP expression was analyzed by fluorescence microscopy and FACS. The GFP expression was stronger in 372 bp promoter (−116∼+256 bp) group than others in NIH3T3 and MEL cells (Fig. 3a,b) . FACS analysis also showed that the proportion of GFP positive MEL cells was (11.2 ± 0.6)% driven by 372 bp-length promoter significantly higher than others. In contrast, the GFP expression level driven by 372 bp-length promoter in NIH3T3 cells was (31.0 ± 0.7)%, a little higher than other groups ( Table 2) . The results demonstrated the 372 bp-length promoter is the most effective one and that the GFP expression driven by 372 bp-length EDRF promoter may be tissue-specific expression. Construction of pcDNA-EDRF vector and detection of EDRF cDNA by RT-PCR Considering the results above showing the 372 bplength promoter to be more effective as well as in order to further investigate the role of EDRF to β-thalassemia, we constructed pcDNA-EDRF vector in which the 372 bp promoter was used to drive the EDRF expression (Fig. 2b) . The pcDNA-EDRF vector was then isolated according to the manufacturer's instructions (Promega). Forty-eight h after the MEL cells were treated with vectors, total RNA was isolated and cDNA was synthesized at 37
• C for 1 h. RT-PCR results showed that the human EDRF can express effectively in MEL cells (Fig. 4) . 
Human EDRF expression detected in mice
To study the expression of EDRF in mice blood, the healthy mice were injected with pcDNA-EDRF by tail vein. One week later, hematologic studies were analyzed. RT-PCR showed that human EDRF expressed effectively in the mice ( Fig. 5; lane 2) . ELISA illustrated that EDRF expressed about 4 mg/mL after pcDNA-EDRF treatment (Fig. 6) . The results thus demonstrated that pcDNA-EDRF driven by the 372 bp promoter could express effectively in mice body. Ameliorating anemia in β 654 -thalassemia mice Decreased or defective EDRF would be expected to worsen the phenotype of β-thalassemia because of the cytotoxic effects of excessive free α-hemoglobin. For this reason, the above described pcDNA-EDRF vector was used to study the therapeutic effect to β-thelassemia. After β-thelassemia mice was treated with pcDNA-EDRF vector, peripheral blood smears and the hematological observations were analyzed. One week after treatment with pcDNA-EDRF, the total quantity of poikilocytosis plus target cells in the peripheral blood smear of β-thelassemia mice treated with pcDNA-EDRF was (38.4 ± 2.3)%, less than (52.8 ± 3.4)% before treatment (p = 0.000, n = 5) (Fig. 7) . The hemoglobin value was about (7.93 ± 0.2) g/dL after treatment, higher than that before treatment, which was (7.1 ± 0.3) g/dL (p = 0.034, n = 5). The red blood cells counts were also improved from 5.5 × 10 6 /µL before treatment to 6.4 × 10 6 /µL after treatment (p = 0.009, n = 5). In contrast, the control mice treatment with pcDNA(3.1+)/ZEO still showed marked anisocytosis, poikilocytosis plus target cells, which was changed from (48.7 ± 3.5)% before treatment to (48.4 ± 1.9)% after treatment (p = 0.82, n = 5). The hemoglobin value within the control mice was not improved, which was changed from (7.5 ± 0.3) g/dL before treatment to (7.6 ± 0.3) g/dL after treatment (p = 0.67, n = 5). When total RNA of the mice blood was analyzed by RT-PCR, the results demonstrated that human EDRF was expressed highly in pcDNA-EDRF treatment mice (Fig. 5, lanes 4,5) . ELISA results also showed that human EDRF expressed about 4 mg/mL in pcDNA-EDRF treatment mice (Fig. 6 ), which indicated that the possible mechanism of the improved peripheral blood smears may be relevant to systemic EDRF expression level.
Discussion
Previous studies have made progress in gene therapy to β-thalassemia in cultured cells or in mouse models by increasing non-α-globin (β-or γ-globin), such as increasing β-globin expression by antisense RNA restoring abnormal splicing transcription (Vacek et al. 2003) , genetic manipulation in autologous hematopoietic stem cells (May et al. 2000 (May et al. , 2002 , and gene transfer com-bined with RNA interference technologies (Samakoglu et al. 2006 ). Here we attempted a novel strategy to treat β-thalassemia by stabilizing α-globin using EDRF. We observed enhanced erythropoiesis, ameliorated poikilocytosis and target cells in β-thalassemia mice after treatment with expressing EDRF vector. Also, the amelioration of the anemia syndrome of β-thalassemia mice was attributed to cloning effective promoter to drive EDRF expression. Our data provide convincing evidence demonstrating the therapeutic potential of EDRF in the management of β-thalassemia in mice.
Hyperexpression of the transgenic gene in vitro and in vivo is relevant to different promoters' sequences, which are the regulation sites of transcription factors (Kordower & Olanow 2008; Nagamine 2008) . In this study five kinds of different-length promoters of EDRF (697 bp, 496 bp, 484 bp, 372 bp, 283 bp) were amplified to select the effective sequence for gene therapy. After different EDRF promoter sequences were cloned to drive a GFP reporter gene expressionin vitro, the 372 bp EDRF promoter (−116∼+256 bp) was found to direct the GFP expression most effectively. The site (−116∼+256 bp) in our results agreed with other studies, which reported numerous consensus GATA-1 (transcription factor) binding sites in EDRF gene (Shirihai et al. 2000; Keys et al. 2007 ), including the minimal (−170∼+296 bp) promoter region (Gallagher et al. 2005) .
The Oct-1 (transcription factor) binding site was also considered to construct vectors in this study. The −116∼+256 bp of EDRF promoter, which was the binding site of Oct-1, was cloned and found to increase the GFP expression in MEL cells. The Oct-1 site is crucial for EDRF expression, mutation of which can reduce 60% of promoter's activity (Gallagher et al. 2005) . The cause may be that Oct-1 is a ubiquitously expressed member of the so-called POU domain family of transcription factors known to regulate numerous tissuespecific and ubiquitous genes as transcriptional activators (Herr & Cleary 1995; Andersen & Rosenfeld 2001) . Based on the above studies, the pcDNA-EDRF vector composing the Oct-1 binding site was further constructed and found to effectively express human EDRF in MEL cells and in vivo in mice.
Another new finding is that the GFP expression was lower when driven by 484 bp (F2-R2) promoter than that driven by 372 bp promoter, which demonstrated that there may be a possible attenuator between primers F2 and F3 (−228∼+116 bp). Further mutation experiment is necessary to prove the detail site region and sequence.
Therapeutic efficacy was also evaluated by investigating the improved anemia manifestation of β-thalassemia mice (Hbb th−4 /Hbb + ), which are known to be a useful model system to study gene therapy action by using EDRF to β-thalassemia. In this animal model heterozygous mice (Hbb th−4 /Hbb + ) present reduced amounts of the mouse β-globin chains and no functional human β-globin, and have an intermediate form of β-thalassemia (Lewis et al. 1998) . The experimental results showed that the hemoglobin value, poikilocytosis and target cells were ameliorated when β-thalassemia mice were treated with pcDNA-EDRF plasmids. The improvement of hematological parameters of experimental mice may be relevant to the expression of human EDRF, because EDRF deficiency can worsen the phenotype in β-thalassemic mice as a modifier gene influencing the phenotype of β-thalassemia syndromes (dos Santos et al. 2004; Keys et al. 2007 ).
In conclusion, our study demonstrated that the 372 bp promoter (−116∼+256 bp) of EDRF was the most effective sequence for promoting the EDRF gene expression. In addition, the anemia manifested by β-thalassemia mice was ameliorated after EDRF plasmids treatment. This study provides a potential approach for β-thalassemia therapy.
